Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.3
4.3
Journals
Antibiotics
Special Issues
Antibiotic Strategy for the Treatment of Infections in Specific Populations
share announcement

Antibiotic Strategy for the Treatment of Infections in Specific Populations

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 3041

Special Issue Editor

Dr. Hideo Kato

E-Mail Website
Guest Editor
1. Department of Pharmacy, Mie University Hospital, Mie 5148507, Japan
2. Department of Clinical Pharmaceutics, Mie University Graduate School of Medicine, Mie 5148507, Japan
3. Department of Clinical Infectious Diseases, Aichi Medical University, Aichi 4801195, Japan
Interests: infections and antibiotic use; efficacy and safety of antibiotics; antibiotic resistance; PK/PD study; animal infectious model; meta-analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recently, international and domestic guidelines for appropriate selection and dosage of antimicrobial agents have undergone revision. A central component of its appropriate use is involved in pharmacokinetics/pharmacodynamics (PK/PD) theory. This theory considers the appropriate dosage and administration methods on the basis of the pharmacokinetics of drugs and the characteristics of each drug based on blood concentration of drugs; this information is used to determine the method of administration of antimicrobial agents. However, the PK/PD parameters such as area under the curve (AUC)/minimum inhibitory concentration (MIC), Cmax/MIC, and time above MIC need to be investigated since there is limited number of studies targeting patients with specific backgrounds. The absence of work is particularly marked with regard to patients receiving renal replacement therapy, children, elderly, and so on. In addition, despite huge difference in PK among infections, antibiotics are constant in dosage. Therefore, the ideal antibiotic strategy for use in these specific populations is controversial.

We welcome papers reporting original data from epidemiologic studies, as well as systematic reviews and meta analyses, especially those providing novel antibiotic strategies designed to overcome resistant pathogens in patients receiving renal replacement therapy.

Dr. Hideo Kato
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 559 KiB  
Article
A Retrospective Study on the Effectiveness and Safety of Vancomycin versus Daptomycin in Hemodialysis Patients
by Hideo Kato, Mao Hagihara, Mariko Kato, Yuka Yamagishi, Takumi Umemura, Nobuhiro Asai, Jun Hirai, Takuya Iwamoto and Hiroshige Mikamo
Antibiotics 2022, 11(6), 710; https://doi.org/10.3390/antibiotics11060710 - 25 May 2022
Cited by 3 | Viewed by 2300
Abstract
Vancomycin or daptomycin is administered to hemodialysis patients infected with methicillin-resistant Staphylococcus and Enterococcus species. Although serious concerns regarding nephrotoxicity due to vancomycin have been raised, it might not be a critical issue in hemodialysis patients. Moreover, very few studies have investigated the [...] Read more.
Vancomycin or daptomycin is administered to hemodialysis patients infected with methicillin-resistant Staphylococcus and Enterococcus species. Although serious concerns regarding nephrotoxicity due to vancomycin have been raised, it might not be a critical issue in hemodialysis patients. Moreover, very few studies have investigated the effectiveness of vancomycin versus daptomycin in patients undergoing hemodialysis. Hence, we retrospectively evaluated the effectiveness and safety of vancomycin and daptomycin in patients undergoing hemodialysis. We investigated the following measures: mortality, clinical and microbiological effectiveness, and incidence of adverse events in hemodialysis patients who received vancomycin or daptomycin from 2014 to 2019. Moreover, we evaluated the covariates related to 30-day mortality. We found that 73 patients received vancomycin, while 34 received daptomycin for the treatment of infections due to methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative Staphylococci, and Enterococcus faecium. Mortality after vancomycin treatment was significantly lower than daptomycin treatment (4.1% vs. 26.5%, p < 0.01). The clinical and microbiological effectiveness as well as the safety were not significantly different between the two treatments. Although daptomycin treatment with a loading dose was associated with lower mortality, the mortality of the treatment (8.3%) did not differ significantly compared to that of the vancomycin treatment (4.1%). Therefore, our findings suggest that vancomycin remains the first-line treatment for hemodialysis patients; however, a loading dose may be beneficial for patients receiving daptomycin. Full article
(This article belongs to the Special Issue Antibiotic Strategy for the Treatment of Infections in Specific Populations)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop